ALDX

AI Memo

Aldeyra Therapeutics

As of 2026-09-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

FDA interaction and potential resubmission plan • 2026-12-05

Base target: $2 / p=50% prob

Biggest risk

The FDA rejection leaves Aldeyra without a clear near-term approval or commercialization path. Forward visibility is weak, pipeline programs remain early, and financing, dilution, clinical, and regulatory execution risks remain material.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Regulatory clarity or a credible resubmission path for reproxalap could re-rate the shares, while the RASP pipeline and projected runway provide longer-term optionality. The ADX-629 data were positive but based on a small exploratory study.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-06

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

FDA complete response letter remains the dominant overhang
Next-generation RASP pipeline and runway
Regulatory clarity or a credible resubmission path for reproxalap could re-rate the shares, while the RASP pipeline and projected runway provide longer-term optionality.

BearKey bullets

Clinical and regulatory execution risk across next-generation RASP programs.
Loose peer set and unavailable analyst-revision, options, short-interest, and social-coverage data limit confidence in relative valuation and positioning.
Potential financing or dilution risk if development costs extend beyond the projected runway.

WatchKey bullets

FDA interaction and potential resubmission plan

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=50%)

Target spread vs base: +119% / -62%

Scenario probabilities

Bull Target: $4 (p=20%)Base Target: $2 (p=50%)Bear Target: $1 (p=30%)

Commentary

The available headline narrative is mixed-to-negative, dominated by the FDA rejection and regulatory uncertainty, while positive pipeline and runway context is older. A June CEO open-market purchase is secondary alignment evidence only and does not establish operating improvement [#SEC-FORM4-2026-06-05]. Social, options, short-interest, employee-review, and analyst-revision data are unavailable; zeros indicate unavailable data, not neutral evidence. This remains a low-coverage, event-driven monitoring view.

As of 2026-09-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

FDA complete response letter remains the dominant overhang
Next-generation RASP pipeline and runway

Scenarios

Bull Target (Scenario probability)

$4 / p=20% prob

Base Target (Scenario probability)

$2 / p=50% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-09-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.45

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-05
FDA interaction and potential resubmission plan
The company reported that it scheduled a Type A meeting with the FDA to understand actions needed for reproxalap approval. A clearer regulatory plan could improve sentiment, but meeting timing and any resubmission requirements remain uncertain [#SEC-10Q-2026-05-07; #IR-2026-03-17].
Prob 45.00% • Move 25.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

FDA complete response letter remains the dominant overhang
2026-12-05
Aldeyra received a March 2026 FDA complete response letter for reproxalap’s dry-eye NDA. The approval path, required actions, timing, and probability of eventual approval remain uncertain, keeping downside and event volatility elevated [#IR-2026-03-17].
Prob 70% • Move -25% • Priced-in 70%

Long-term Catalysts

Months to a year

Next-generation RASP pipeline and runway
2026-12-31
Aldeyra reported positive exploratory ADX-629 Phase 2 results, shifted development focus to ADX-248 and ADX-246, targeted 2026 IND filings, and extended projected operating runway into the second half of 2027. These remain early-stage optionality rather than near-term revenue drivers [#PR-EARNINGS-2025-10-28].
Prob 35% • Move 20% • Priced-in 20%

Risks

Clinical and regulatory execution risk across next-generation RASP programs.
Loose peer set and unavailable analyst-revision, options, short-interest, and social-coverage data limit confidence in relative valuation and positioning.
Potential financing or dilution risk if development costs extend beyond the projected runway.
Unresolved FDA complete response letter and uncertain reproxalap resubmission or approval path.

Peers

Symbol	Summary
BNR	Loose same-sector, similar-market-cap biotech comparator; direct clinical and indication comparability is unconfirmed.
CGTX	Similar-market-cap biotechnology comparator, but the packet does not support a decision-useful operating comparison.
FBIO	Loose same-sector, similar-market-cap comparator; not established as a direct reproxalap or RASP peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-06

Loading AI feed…

Symbol

Summary

BNR

Loose same-sector, similar-market-cap biotech comparator; direct clinical and indication comparability is unconfirmed.

CGTX

Similar-market-cap biotechnology comparator, but the packet does not support a decision-useful operating comparison.

FBIO

Loose same-sector, similar-market-cap comparator; not established as a direct reproxalap or RASP peer.